<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Numerous studies have shown the pathological influence anti-<z:chebi fb="0" ids="16247">phospholipid</z:chebi> antibodies (APLA) have on the <z:mp ids='MP_0001532'>physiology</z:mp> of the single neuron as well as the function of the entire human <z:mp ids='MP_0008912'>nervous</z:mp> system </plain></SENT>
<SENT sid="1" pm="."><plain>The influence is well demonstrated in the <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> (APS) </plain></SENT>
<SENT sid="2" pm="."><plain>This syndrome is characterized by a triad of arterial or venous thrombotic events, recurrent fetal loss and thrombocytopenic <z:hpo ids='HP_0000979'>purpura</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>The syndrome exhibits different neurological pathologies such as: <z:hpo ids='HP_0002072'>chorea</z:hpo>, <z:hpo ids='HP_0001250'>seizures</z:hpo>, transverse <z:hpo ids='HP_0002196'>myelopathy</z:hpo>, <z:hpo ids='HP_0002076'>migraine</z:hpo>, cerebral <z:hpo ids='HP_0001251'>ataxia</z:hpo>, <z:hpo ids='HP_0100248'>hemiballismus</z:hpo> and <z:hpo ids='HP_0010534'>transient global amnesia</z:hpo>, which are not fully explained by the procoagulopathic trait of APLA </plain></SENT>
<SENT sid="4" pm="."><plain>A study on mice induced with APS demonstrated <z:hpo ids='HP_0000752'>hyperactive behavior</z:hpo> when compared to the control group </plain></SENT>
<SENT sid="5" pm="."><plain>The information gathered from these different studies raised the question whether APLA has any part in the etiology of <z:hpo ids='HP_0007018'>Attention Deficit</z:hpo>/<z:mp ids='MP_0001399'>Hyperactive</z:mp> Disorder (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ADHD</z:e>) in children </plain></SENT>
<SENT sid="6" pm="."><plain>We compared 41 children diagnosed with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ADHD</z:e> to a control of 28 healthy children </plain></SENT>
<SENT sid="7" pm="."><plain>Blood drawn from the two groups was screened using ELISA for the presence of anti-<z:chebi fb="0" ids="28494">cardiolipin</z:chebi> antibodies, anti-beta2GP antibodies, anti-phosphatidyleserine antibodies and anti-<z:chebi fb="0" ids="16000,23981">ethanolamine</z:chebi> antibodies </plain></SENT>
<SENT sid="8" pm="."><plain>The results show no significant difference in the level of <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> (APLA) measured between the children diagnosed with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ADHD</z:e> and the control group </plain></SENT>
</text></document>